Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Allergen-crosslinked IgE triggers allergy by interacting with its receptor on basophils and mast cells. The anti-IgE monoclonal antibody omalizumab can alleviate allergy by competing with the receptor for IgE binding. However, along with neutralization, omalizumab also inhibits IgE degradation, which is clinically associated with high-dose and total IgE accumulation problems. In this study, we have developed an IgE-eliminating antibody on the basis of omalizumab, which has pH-dependent Fabs and an Fc with high affinity for FcγRIIb. In mice, the antibody rapidly eliminated total serum IgE to baseline levels and caused lower free IgE levels than omalizumab. At low dosages, the antibody also exhibited favorable IgE elimination effects. In addition, the antibody can degrade the corresponding allergen with the removal of IgE, addressing the allergy from its source. Introduction of the M252Y/S254T/T256E (YTE) mutation into this antibody prolongs its serum half-life without reducing potency. Thus, this engineered antibody holds a promising therapeutic option for allergy patients. Mechanistic insights are also included in this study.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489548 | PMC |
| http://dx.doi.org/10.1016/j.ymthe.2024.08.029 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Engrafted NSG-SGM3 humanized mice spontaneously produce human immunoglobulins including IgE.
Front Immunol
September 2025
Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
NSG-SGM3 humanized mouse models are well-suited for studying human immune physiology but are technically challenging and expensive. We previously characterized a simplified NSG-SGM3 mouse, engrafted with human donor CD34 hematopoietic stem cells without receiving prior bone marrow ablation or human secondary lymphoid tissue implantation, that still retains human mast cell- and basophil-dependent passive anaphylaxis responses. Its capacities for human antibody production and human B cell maturation, however, remain unknown.
View Article and Find Full Text PDFMicroenvironment-Driven Mast Cell Plasticity: Insights From Cytokine-Activated Gene Signatures in Skin and Respiratory Diseases.
Allergy
September 2025
Department of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, Lydia Becker Institute of Immunology and Inflammation, The University of Manchester, Manchester, UK.
Mast cells (MCs) rapidly adapt to the microenvironment due to the plethora of cytokine receptors expressed. Understanding microenvironment-primed immune responses is essential to elucidate the phenotypic/functional changes MCs undergo, and thus understand their contribution to diseases and predict the most effective therapeutic strategies. We exposed primary human MCs to cytokines mimicking a T1/pro-inflammatory (IFNγ), T2/allergic (IL-4 + IL-13), alarmin-rich (IL-33) and pro-fibrotic/pro-tolerogenic (TGFβ) microenvironment.
View Article and Find Full Text PDFMulti-Omic Analysis of Scylla serrata Reveals the Allergen Landscape of Mud Crabs and Decapoda Species.
Allergy
September 2025
School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong SAR, China.
Matrine alleviates the immune imbalance of atopic dermatitis by up-regulating FOXO4 to inactivate circTNFRSF21-mediated JAK/STAT3 axis.
Immunopharmacol Immunotoxicol
September 2025
Department of Dermatology, The Second Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, Hunan Province, China.
Objective: Atopic dermatitis (AD) is a common chronic inflammatory skin problem. Herein, we aimed to demonstrate the efficacy of matrine (MT) on AD and to reveal its mechanism.
Material And Methods: An AD model was induced topical administration of 1-fluoro-2,4-dinitorobenzene (DNFB).
Retrospective study about suppression of new sensitization to cedar pollen in children who have undergone sublingual immunotherapy for house dust mites.
Auris Nasus Larynx
September 2025
Osaka Habikino Medical Center -Pediatrics, Osaka, Japan.
Objective: To investigate whether sublingual immunotherapy (SLIT) with house dust mite (HDM) extract suppresses new sensitization to Japanese cedar pollen(JCP) in children with HDM-positive allergic rhinitis.
Methods: This retrospective study was conducted at our center and included pediatric patients aged 5-15 years who visited between January 2018 and December 2020. Eligible patients tested positive for HDM-specific immunoglobulin E (IgE), negative for JCP-specific IgE, and had no history of SLIT for cedar pollen.